Will you be automatically switched to a generic?

For most patients covered by private insurance, the transition to generic semaglutide will likely happen at the pharmacy level without requiring action on your part. When a generic enters the Canadian market, insurers typically update their formularies to list the generic as the preferred product. In practice, this means your pharmacist may dispense the generic version at your next refill unless your physician has specified that the brand-name product is medically necessary.

Both approved generics are expected to launch soon. Apotex has publicly stated it expects to bring its product to market in the very near future, though exact pharmacy availability dates have not been formally confirmed by either manufacturer. For most private plans, coverage of new generics typically follows shortly after they become commercially available.

If you have concerns about switching, or if you have experienced issues with formulation changes in the past, it is worth speaking with your prescribing physician before your next refill. They can note a preference on your prescription if there is a clinical reason to remain on the brand-name product. Patients may also request the brand-name product based on personal preference, though this will often result in higher out-of-pocket costs if your insurer has designated the generic as the preferred product.

For patients covered by provincial public drug plans, the transition is generally more structured. Provincial plans typically move to reimburse only the generic once one becomes available, though timelines and listing decisions vary by province. Health Canada authorization does not automatically trigger formulary listing; each province makes that decision separately. If you are currently receiving provincial coverage for Ozempic, contact your provincial drug benefit program or pharmacist for specific guidance on how the transition will be handled in your province.

Is a generic version of Ozempic as effective as the original?

Yes, based on Health Canada's review criteria. To receive authorization, generic semaglutide manufacturers must demonstrate that their product contains the same active ingredient at the same strength and dose, works the same way in the body, and meets the same safety, efficacy, and quality standards as the brand-name version.

Health Canada has confirmed that both approved generics are pharmaceutically equivalent to Ozempic. The agency noted that differences between the generic and brand-name products do not affect safety, efficacy, or quality.

It is worth noting that semaglutide is a more complex molecule than a typical generic drug. Unlike a conventional small-molecule pill, semaglutide is a synthetic peptide delivered by injection, which is why Health Canada's review process involved additional scrutiny. That scrutiny is also why generic approval took longer than it does for most drug classes. Side effects with generic versions are expected to be similar to the brand-name product, as the active ingredient and dose are the same.

How much less will a generic cost?

Pricing for publicly funded drug plans is governed by the pan-Canadian Pharmaceutical Alliance (pCPA) tiered framework, based on how many generic manufacturers are in the Canadian market:

• One generic (single source): Enters at 85% of the brand reference price, or 75% if a pricing agreement with provincial plans exists; automatically drops to 55% after three months of public funding
• Two generics (dual source): Price for both falls to 50% of the brand reference price
• Three or more generics (multi source): Price falls to 35% of the brand reference price for injectables like semaglutide

For context, recent Canadian list and retail pricing for brand-name Ozempic has generally been in the low hundreds of dollars per month before insurance, varying by dose, pharmacy, and province.

It is important to note that the pCPA tiers govern what provincial public drug plans pay, not what patients pay directly at the counter. Actual out-of-pocket costs will depend on your insurance coverage, whether your province has listed the generic on its formulary, and the retail pricing set by individual pharmacies. With two generics now approved and seven additional submissions under review, meaningful price compression is anticipated over the coming months. Your pharmacist will be able to confirm the exact cost of the generic at your refill once one becomes available. 

For more information on how the tiered pricing framework works, see the pCPA's generic drug framework.

Does the new cardiovascular indication change anything about eligibility or coverage?

On March 2, 2026, Health Canada approved a new indication for Ozempic: reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who also have established cardiovascular disease or chronic kidney disease. It does not change the existing approved use for blood sugar management.

For patients who fall into this category, the practical implications are twofold. It gives your prescribing physician stronger clinical grounds to recommend Ozempic as part of a treatment plan that addresses both glycemic control and cardiovascular risk simultaneously. It may also have implications for insurance coverage, as insurers occasionally revise coverage criteria when a drug receives an expanded indication.

If you have type 2 diabetes and have been diagnosed with heart disease or chronic kidney disease, it is worth raising this with your physician or endocrinologist at your next appointment. 

For a full breakdown of the clinical trial evidence behind this approval, see our earlier article: Ozempic now approved to reduce cardiovascular risk in adults with type 2 diabetes.

What should you do now?

If you are currently taking Ozempic for type 2 diabetes:

• Expect a possible generic substitution at your next refill. If you have concerns, speak with your physician before it occurs. Expect a possible generic substitution at your next refill. Your pharmacist will notify you when a generic is being dispensed and can answer questions about the switch, including any cost differences. If you have a specific clinical reason to remain on the brand-name product, speak with your physician.
• If you also have cardiovascular disease or chronic kidney disease, raise the new indication with your care team. It may be relevant to how your treatment is documented and covered.
• Check with your pharmacist or insurer about when their formulary will be updated to include generic semaglutide.

If you are considering Ozempic for type 2 diabetes:

• The arrival of generics makes access more realistic for patients who have previously been deterred by cost.
• A consultation with a licensed physician is still required. Eligibility is determined based on your individual medical history and treatment goals.
• Endor Health’s partnered pharmacies can fill Ozempic prescriptions with free delivery and direct insurance billing across Canada.

Sources

1. Health Canada. (April 28, 2026). Canada becomes the first G7 country to approve a generic version of semaglutide.
2. Health Canada. (May 1, 2026). Canada approves second generic semaglutide, the first G7 country to do so.
3. Apotex Inc. (May 1, 2026). Apotex becomes the first Canadian-based global pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic.
4. Novo Nordisk Canada. (March 2, 2026). Health Canada approves Ozempic (semaglutide injection) to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes.
5. pan-Canadian Pharmaceutical Alliance. Generic drug framework: pan-Canadian Tiered Pricing Framework.

For the original patent expiry and background on generic semaglutide in Canada, see Generic Ozempic coming to Canada: what the patent expiry means for people with diabetes.